UBS raised the firm’s price target on Medtronic (MDT) to $95 from $94 and keeps a Neutral rating on the shares. Medtronic now has the pieces in place, but execution remains the key for reaccelerating organic sales growth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $96 from $94 at Baird
- Medtronic price target raised to $98 from $97 at Bernstein
- Medtronic’s Strong Financial Performance and Positive Outlook Justify Buy Rating
- Medtronic price target raised to $100 from $98 at Wells Fargo
- Positive Outlook for Medtronic Amid Strategic Changes and Elliott Management Investment